These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 19168292)

  • 1. N-methyl-D-aspartate receptor antagonists for migraine: a potential therapeutic approach.
    Ye R; Kong X; Han J; Zhao G
    Med Hypotheses; 2009 May; 72(5):603-5. PubMed ID: 19168292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of pan- and subtype-selective N-methyl-D-aspartate receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine.
    Peeters M; Gunthorpe MJ; Strijbos PJ; Goldsmith P; Upton N; James MF
    J Pharmacol Exp Ther; 2007 May; 321(2):564-72. PubMed ID: 17267580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of NR2B-selective antagonist recognition by N-methyl-D-aspartate receptors.
    Mony L; Krzaczkowski L; Leonetti M; Le Goff A; Alarcon K; Neyton J; Bertrand HO; Acher F; Paoletti P
    Mol Pharmacol; 2009 Jan; 75(1):60-74. PubMed ID: 18923063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic N-methyl-D-aspartate receptor antagonists: will reality meet expectation?
    Smith PF
    Curr Opin Investig Drugs; 2003 Jul; 4(7):826-32. PubMed ID: 14619404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamate-based therapeutic approaches: NR2B receptor antagonists.
    Gogas KR
    Curr Opin Pharmacol; 2006 Feb; 6(1):68-74. PubMed ID: 16376149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NMDA receptor subunits: function and pharmacology.
    Paoletti P; Neyton J
    Curr Opin Pharmacol; 2007 Feb; 7(1):39-47. PubMed ID: 17088105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological implications of two distinct mechanisms of interaction of memantine with N-methyl-D-aspartate-gated channels.
    Chen HS; Lipton SA
    J Pharmacol Exp Ther; 2005 Sep; 314(3):961-71. PubMed ID: 15901795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renaissance of NMDA receptor antagonists: do they have a role in the pharmacotherapy for alcoholism?
    Nagy J
    IDrugs; 2004 Apr; 7(4):339-50. PubMed ID: 15057640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamate as a therapeutic target in psychiatric disorders.
    Javitt DC
    Mol Psychiatry; 2004 Nov; 9(11):984-97, 979. PubMed ID: 15278097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamate receptor antagonists in the management of migraine.
    Chan K; MaassenVanDenBrink A
    Drugs; 2014 Jul; 74(11):1165-76. PubMed ID: 25030431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel NMDA receptor antagonist, 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid, is a gating modifier in cultured mouse cortical neurons.
    Noh J; Lee ES; Chung JM
    J Neurochem; 2009 Jun; 109(5):1261-71. PubMed ID: 19302475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antagonists of ionotropic glutamate receptors as the object of research in psychopharmacology].
    Bespalov AIu; Evartau EE
    Usp Fiziol Nauk; 1999; 30(1):39-53. PubMed ID: 10205818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NR2A-containing NMDA receptors are required for LTP induction in rat dorsolateral striatum in vitro.
    Li P; Li YH; Han TZ
    Brain Res; 2009 Jun; 1274():40-6. PubMed ID: 19376094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease.
    Koutsilieri E; Riederer P
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S329-31. PubMed ID: 18267259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The NMDA receptor complex as a therapeutic target in epilepsy: a review.
    Ghasemi M; Schachter SC
    Epilepsy Behav; 2011 Dec; 22(4):617-40. PubMed ID: 22056342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The vasodilatory effect of ketamine is independent of the N-methyl-D-aspartate receptor: lack of functional N-methyl-D-aspartate receptors in rat mesenteric artery smooth muscle.
    Noh HJ; Bae YM; Park SH; Kim JG; Kim B; Kim YS; Kim SH; Cho SI; Woo NS
    Eur J Anaesthesiol; 2009 Aug; 26(8):676-82. PubMed ID: 19352184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabotropic glutamate receptor 1 activity generates persistent, N-methyl-D-aspartate receptor-dependent depression of hippocampal pyramidal cell excitability.
    Clement JP; Randall AD; Brown JT
    Eur J Neurosci; 2009 Jun; 29(12):2347-62. PubMed ID: 19490024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways.
    Chizh BA
    J Psychopharmacol; 2007 May; 21(3):259-71. PubMed ID: 17591654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurological deterioration as a potential alternative endpoint in human clinical trials of experimental pharmacological agents for treatment of severe traumatic brain injuries. Executive Committee of the International Selfotel Trial.
    Morris GF; Juul N; Marshall SB; Benedict B; Marshall LF
    Neurosurgery; 1998 Dec; 43(6):1369-72; discussion 1372-4. PubMed ID: 9848851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.